2cureX AB (publ) (2CUREX.ST)
SEK 0.4
(-5.24%)
SEK 0.4
(-5.24%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.93 Million SEK | -36.51% |
| 2022 | 4.62 Million SEK | -4.01% |
| 2021 | 4.81 Million SEK | 15.22% |
| 2020 | 4.18 Million SEK | -57.19% |
| 2019 | 9.76 Million SEK | -6.15% |
| 2018 | 10.4 Million SEK | 298.81% |
| 2017 | 2.6 Million SEK | -10.86% |
| 2016 | 2.92 Million SEK | -24.51% |
| 2015 | 3.87 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 4.26 Million SEK | 45.28% |
| 2024 Q2 | 4.26 Million SEK | 0.0% |
| 2023 Q1 | 2.9 Million SEK | -37.23% |
| 2023 Q4 | 2.93 Million SEK | -21.52% |
| 2023 FY | 2.93 Million SEK | -36.51% |
| 2023 Q3 | 3.74 Million SEK | 55.64% |
| 2023 Q2 | 2.4 Million SEK | -17.2% |
| 2022 Q3 | 3.6 Million SEK | 27.27% |
| 2022 Q1 | 2.88 Million SEK | -40.05% |
| 2022 FY | 4.62 Million SEK | -4.01% |
| 2022 Q4 | 4.62 Million SEK | 28.31% |
| 2022 Q2 | 2.83 Million SEK | -1.94% |
| 2021 Q2 | 5.52 Million SEK | 46.31% |
| 2021 Q1 | 3.77 Million SEK | -9.59% |
| 2021 Q3 | 3.42 Million SEK | -38.02% |
| 2021 Q4 | 4.81 Million SEK | 40.53% |
| 2021 FY | 4.81 Million SEK | 15.22% |
| 2020 Q1 | 6.38 Million SEK | -34.63% |
| 2020 FY | 4.18 Million SEK | -57.19% |
| 2020 Q2 | 10.03 Million SEK | 57.2% |
| 2020 Q4 | 4.18 Million SEK | -38.48% |
| 2020 Q3 | 6.79 Million SEK | -32.29% |
| 2019 Q1 | 9.14 Million SEK | -12.13% |
| 2019 Q4 | 9.76 Million SEK | -21.15% |
| 2019 Q2 | 7.2 Million SEK | -21.21% |
| 2019 Q3 | 12.38 Million SEK | 71.92% |
| 2019 FY | 9.76 Million SEK | -6.15% |
| 2018 Q3 | 12.83 Million SEK | -21.48% |
| 2018 FY | 10.4 Million SEK | 298.81% |
| 2018 Q4 | 10.4 Million SEK | -18.96% |
| 2018 Q2 | 16.35 Million SEK | 5.58% |
| 2018 Q1 | 15.48 Million SEK | 493.6% |
| 2017 Q3 | 1.16 Million SEK | 0.0% |
| 2017 FY | 2.6 Million SEK | -10.86% |
| 2017 Q1 | - SEK | -100.0% |
| 2017 Q4 | 2.6 Million SEK | 124.5% |
| 2016 FY | 2.92 Million SEK | -24.51% |
| 2016 Q4 | 2.92 Million SEK | 0.0% |
| 2015 FY | 3.87 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 97.247% |
| Ziccum AB (publ) | 6.38 Million SEK | 54.054% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -24.417% |
| BioArctic AB (publ) | 139.5 Million SEK | 97.896% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 91.518% |
| Mendus AB (publ) | 51.22 Million SEK | 94.27% |
| Genovis AB (publ.) | 98.04 Million SEK | 97.007% |
| Intervacc AB (publ) | 21.68 Million SEK | 86.462% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 89.011% |
| Active Biotech AB (publ) | 13.4 Million SEK | 78.097% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 97.633% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 81.789% |
| Aptahem AB (publ) | 8.99 Million SEK | 67.381% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 92.817% |
| Kancera AB (publ) | 17.97 Million SEK | 83.674% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 93.644% |
| Fluicell AB (publ) | 8.91 Million SEK | 67.078% |
| Saniona AB (publ) | 86.08 Million SEK | 96.59% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | 43.098% |
| Biovica International AB (publ) | 34.76 Million SEK | 91.558% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 74.846% |
| AcouSort AB (publ) | 10.37 Million SEK | 71.719% |
| Xintela AB (publ) | 14.01 Million SEK | 79.058% |
| Abliva AB (publ) | 16.78 Million SEK | 82.51% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 98.632% |
| Karolinska Development AB (publ) | 11.56 Million SEK | 74.63% |
| OncoZenge AB (publ) | 1.69 Million SEK | -72.749% |
| Amniotics AB (publ) | 10.54 Million SEK | 72.172% |
| CombiGene AB (publ) | 4.15 Million SEK | 29.379% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | 33.687% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.813% |
| Camurus AB (publ) | 414.81 Million SEK | 99.292% |
| Corline Biomedical AB | 6.78 Million SEK | 56.768% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 95.217% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 84.685% |
| I-Tech AB | 16.2 Million SEK | 81.888% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.753% |
| Cyxone AB (publ) | 4.69 Million SEK | 37.473% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 77.979% |
| Biosergen AB | 5.08 Million SEK | 42.281% |
| Cantargia AB (publ) | 54.97 Million SEK | 94.661% |
| NextCell Pharma AB | 13.68 Million SEK | 78.56% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 95.915% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 78.688% |
| Nanologica AB (publ) | 79.32 Million SEK | 96.3% |
| SynAct Pharma AB | 51.83 Million SEK | 94.338% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | 63.077% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | 43.503% |
| LIDDS AB (publ) | 3.75 Million SEK | 21.858% |
| Lipum AB (publ) | 7.53 Million SEK | 61.064% |
| BioInvent International AB (publ) | 90.45 Million SEK | 96.755% |
| Alzinova AB (publ) | 9.33 Million SEK | 68.546% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 98.384% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -63.601% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 84.13% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | 23.528% |
| Simris Alg AB (publ) | 148.93 Million SEK | 98.029% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 95.873% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 99.391% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 76.97% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | 59.573% |